1. Home
  2. EDSA vs LRHC Comparison

EDSA vs LRHC Comparison

Compare EDSA & LRHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EDSA
  • LRHC
  • Stock Information
  • Founded
  • EDSA 2015
  • LRHC 2004
  • Country
  • EDSA Canada
  • LRHC United States
  • Employees
  • EDSA N/A
  • LRHC N/A
  • Industry
  • EDSA Biotechnology: Pharmaceutical Preparations
  • LRHC
  • Sector
  • EDSA Health Care
  • LRHC
  • Exchange
  • EDSA Nasdaq
  • LRHC Nasdaq
  • Market Cap
  • EDSA 6.2M
  • LRHC 5.4M
  • IPO Year
  • EDSA N/A
  • LRHC 2023
  • Fundamental
  • Price
  • EDSA $1.96
  • LRHC $0.13
  • Analyst Decision
  • EDSA Strong Buy
  • LRHC
  • Analyst Count
  • EDSA 1
  • LRHC 0
  • Target Price
  • EDSA $21.00
  • LRHC N/A
  • AVG Volume (30 Days)
  • EDSA 34.1K
  • LRHC 5.4M
  • Earning Date
  • EDSA 05-14-2025
  • LRHC 05-29-2025
  • Dividend Yield
  • EDSA N/A
  • LRHC N/A
  • EPS Growth
  • EDSA N/A
  • LRHC N/A
  • EPS
  • EDSA N/A
  • LRHC N/A
  • Revenue
  • EDSA N/A
  • LRHC $73,874,281.00
  • Revenue This Year
  • EDSA N/A
  • LRHC N/A
  • Revenue Next Year
  • EDSA N/A
  • LRHC N/A
  • P/E Ratio
  • EDSA N/A
  • LRHC N/A
  • Revenue Growth
  • EDSA N/A
  • LRHC 90.36
  • 52 Week Low
  • EDSA $1.55
  • LRHC $0.09
  • 52 Week High
  • EDSA $5.59
  • LRHC $3.36
  • Technical
  • Relative Strength Index (RSI)
  • EDSA 35.93
  • LRHC 41.00
  • Support Level
  • EDSA $1.96
  • LRHC $0.14
  • Resistance Level
  • EDSA $2.06
  • LRHC $0.15
  • Average True Range (ATR)
  • EDSA 0.10
  • LRHC 0.02
  • MACD
  • EDSA -0.00
  • LRHC 0.00
  • Stochastic Oscillator
  • EDSA 30.77
  • LRHC 27.55

About EDSA Edesa Biotech Inc.

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

About LRHC La Rosa Holdings Corp.

La Rosa Holdings Corp operates in the U.S. residential real estate market. It is a holding company for agent-centric, technology-integrated, cloud-based, multi-service real estate companies. The company's business is organized based on the services it provides internally to the agents and to the public, which are residential and commercial real estate brokerage, franchising, real estate brokerage education and coaching, and property management. The company has six reportable segments, namely: Real Estate Brokerage Services (Residential), Franchising Services, Coaching Services, Property Management, Real Estate Brokerage Services (Commercial), and Title Settlement and Insurance. It derives maximum revenue from the Real Estate Brokerage Services (Residential) segment.

Share on Social Networks: